<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093324</url>
  </required_header>
  <id_info>
    <org_study_id>ALK8700-A302</org_study_id>
    <nct_id>NCT03093324</nct_id>
  </id_info>
  <brief_title>A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
  <official_title>A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the gastrointestinal (GI) tolerability of ALKS 8700 in adult subjects
      with RRMS
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days with GI events using an individual GI symptom scale</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure time weighted GI symptom intensity using an individual GI symptom scale</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with overall GI symptoms using a global GI symptom scale</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be measured by incidence of adverse events (AEs)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALKS 8700</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules, administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsules, administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 8700</intervention_name>
    <description>Oral capsules, administered twice daily</description>
    <arm_group_label>ALKS 8700</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethyl Fumarate</intervention_name>
    <description>Oral capsules, administered twice daily</description>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <other_name>Tecfidera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of understanding and complying with the protocol

          -  Has a confirmed diagnosis of RRMS

          -  Neurologically stable with no evidence of relapse within 30 days prior to
             randomization

          -  Agrees to use an acceptable method of contraception for the duration of the study and
             for 30 days after any study drug administration, or is surgically sterile or
             post-menopausal

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Have any finding(s) that would compromise the safety of the subject, affect the
             subject's ability to adhere to the protocol visit schedule or to fulfill visit
             requirements, or would make the subject unsuitable for participation in the study

          -  Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

          -  History of clinically significant cardiovascular, pulmonary, GI, dermatologic,
             psychiatric, neurologic (other than MS), endocrine, renal, and/or other major disease
             that would preclude participation in a clinical trial

          -  History of GI surgery (except appendectomy that occurred more than 6 months prior to
             screening

          -  History of clinically significant recurring or active gastrointestinal symptoms (eg,
             nausea, diarrhea, dyspepsia, constipation) within 3 months of screening

          -  Chronic use (7 days) of medical therapy to treat any GI symptoms within 1 month of
             screening Has a clinically significant medical condition or observed abnormality at
             screening

          -  History of a myocardial infarction, including a silent myocardial infarction or
             unstable angina

          -  History of clinically significant drug or alcohol abuse within the past year prior to
             screening

          -  Clinically significant history of suicidal ideation or suicidal behavior in the last
             12 months

          -  Subject is pregnant or breastfeeding or plans to become pregnant or begin
             breastfeeding at any point during the study and for 30 days after any study drug
             administration

          -  Prior use of Dimethyl Fumarate (DMF)

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Leigh-Pemberton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Rebecca Moore</last_name>
    <phone>512-904-4325</phone>
    <email>EmilyRebecca.Moore@INCResarch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>March 16, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>RRMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>Alkermes</keyword>
  <keyword>ALKS 8700</keyword>
  <keyword>Dimethyl Fumarate</keyword>
  <keyword>DMF</keyword>
  <keyword>Tecfidera</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
